HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 11, November 2017 – Paediatric Illnesses       » Breakthrough new rice variety announced in Northern China       » Ebola vaccine approved in China       » Study reveals anti-cancer properties of a fungus used in traditional medicine       » Chinese scientists create genetically modified low-fat pigs       » China, Brazil and Russia are riskiest markets for compliance and regulation       » Why are Korean eggs salmonella-free?      
INSIDE INDUSTRY
Kinetica helps GlaxoSmithKline manage its R&D information platform
Kinetica uses techniques such as machine learning, deep learning, and natural language processing (NLP) with easy-to-use visual analytics tools to interactively run thousands of simulations across complex data sets, to help GlaxoSmithKline manage its R&D information platform.

GlaxoSmithKline (GSK) is a science-led global healthcare company that researches and develops a broad range of innovative products in three primary areas: pharmaceuticals, vaccines, and consumer healthcare. Their product portfolio includes global medicines for HIV/AIDS, tuberculosis and malaria, as well as a range of consumer brands, including Sensodyne, Aquafresh, Horlicks, Panadol, and Tums.

Having seen the promise of GPU-accelerated compute, GSK had already made a sizable investment in a GPU-accelerated cluster for a specific use case—accelerated chemical simulations. They were using specialised and customised software to run chemical simulations on 125,000 GPU cores. Due to the difficulty of writing parallel code to take advantage of the GPU environment, the cluster was not being taken advantage of for additional use cases. It was not effective for GSK to have such a platform for only one use case, so they were seeking a solution that allowed them to run a multitude of use cases on their GPU cores.

The solution

Kinetica enables GSK’s data science and analytics teams to tap into the power of their existing GPUs, without needing to write custom code or use specialised software for each particular use case. By using Kinetica, GSK is now able to open a plethora of advanced and innovative use cases. By allowing GSK to communicate with their existing GPU cluster just like a typical relational database, users can interact with it using a traditional query language such as SQL.

Now, GSK’s data science and analytics teams can run workloads that require a more computationally-intensive environment for analysis in Kinetica while maintaining the feel of communicating with a traditional relational environment. Below are summaries of a few specific use cases.

User Defined Functions (UDFs) enable advanced analytic workloads across the entire complex

One of the areas the GSK team is most excited about is in the area of machine learning and other types of algorithms. With Kinetica, one of the things they wanted to have was user-defined functions (UDFs). UDFs enable users to add a little payload into their query, and then let the Kinetica optimisation engine spread that across the whole GPU complex.

Additionally, GSK can quickly deploy new models and eliminate the time and effort required to transform data and move it back and forth between a database and a separate data science system. With Kinetica’s user-defined functions, GSK can package up analytics as an extension to the optimisation engine that is running, and let Kinetica do the job for them.

When they are doing advanced machine learning or other types of chemical simulations, GSK can now “turbocharge” them by running those jobs on a GPU complex. Kinetica allows GSK to use the GPU platform for more than just one use case, because each of the use cases suddenly become more like queries than highly customised pieces of software. Kinetica gives GSK a layer of abstraction between the GPU hardware and the workloads that they provide to the platform.

Fast data

GSK has multi-billion row data sets, and they wanted to do aggregations and queries on those datasets. GSK has 125,000 GPU cores, and the organisation did not want to tackle the labour-intensive task of figuring out how to write parallel queries that go across GPU cores. “I don’t want to figure out how to write queries to go across 125k cores. Nima Negahban, Chief Technology Officer and Co-Founder, and the Kinetica team have already solved that problem,” says Mark Ramsey, Ph.D., Senior Vice President, R&D Data, GlaxoSmithKline.

Kinetica’s parallel architecture makes it possible for GSK’s data science and analytics teams to load their relational data into the Kinetica environment, submit a query, and get results back quickly. GSK is seeing 75 to 100 times faster results with Kinetica; they have moved from a more traditional database environment to an accelerated one.

Looking ahead to streaming

Given the emergence of digital devices and upcoming initiatives, GSK plans to make use of streaming technology in the future. At this point, GSK is currently focused on the machine learning and fast data areas, where they can take slower-running queries and turbocharge them, as well as take analytics and machine learning activities and apply them in a very efficient way.

GPU-databases bring next-generation solutions to pharma and healthcare

GPU-accelerated databases are reshaping the pharmaceutical and healthcare industries. Bringing new drugs to market is an expensive, lengthy, and risky process, requiring billions of dollars in upfront investments. With Kinetica’s GPU-accelerated database, healthcare and pharma companies can derive faster insights from vast volumes of streaming data. Kinetica can help researchers use algorithmic techniques such as machine learning, deep learning, and natural language processing (NLP) with easy-to-use visual analytics tools to interactively run thousands of simulations across complex data sets.

Kinetica returns results for advanced analytical queries on billions of rows of data in well under a second, making it an ideal solution for pharmaceutical research. By delivering a fast and powerful data and analytics solution, Kinetica accelerates the drug discovery, development, and clinical trials process while minimising costs, reducing risks, and ultimately, saving lives.

Source: Kinetica

Click here for the complete issue.

NEWS CRUNCH  
news MIT Technology Review announces 2018's 10 'Innovators Under 35 Asia'
news Novogen becomes Kazia Therapeutics
news Transforming healthcare through innovation: addressing unmet healthcare needs in Asia Pacific
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Get to Know TCM
April:
Diabetes: The Big Picture
May:
The Piece of Your Mind - Brain Health/Science
June:
Advocacies in Support of Rare Disease Patients
July:
Food Science & Technology
August:
Eye – the Window to your Soul
September:
Infectious Diseases
October:
A change of heart — Cardiovascular diseases
November:
Paediatric Illnesses
December:
Skin Diseases/Allergic Reactions
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy